These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Randomized, placebo-controlled trial of nonpegylated and pegylated forms of recombinant human alpha interferon 2a for suppression of dengue virus viremia in rhesus monkeys. Ajariyakhajorn C; Mammen MP; Endy TP; Gettayacamin M; Nisalak A; Nimmannitya S; Libraty DH Antimicrob Agents Chemother; 2005 Nov; 49(11):4508-14. PubMed ID: 16251289 [TBL] [Abstract][Full Text] [Related]
25. The comparative anti-herpes simplex virus effects of human interferons. Taylor JL; Little SD; O'Brien WJ J Interferon Cytokine Res; 1998 Mar; 18(3):159-65. PubMed ID: 9555977 [TBL] [Abstract][Full Text] [Related]
26. Resistance to recombinant alpha interferon therapy in idiopathic mixed cryoglobulinemia: reinduction of remission by natural alpha interferon both in antibody-positive and -negative patients. Casato M; Antonelli G; Maggi F; Pucillo LP; Di Lullo L; Leoni M; Currenti M; Dianzani F; Bonomo L J Biol Regul Homeost Agents; 1994; 8(2):56-9. PubMed ID: 7863814 [TBL] [Abstract][Full Text] [Related]
27. Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes. Utsugi T; Sone S J Immunol; 1986 Feb; 136(3):1117-22. PubMed ID: 3079797 [TBL] [Abstract][Full Text] [Related]
28. Antigenic characterization of recombinant, lymphoblastoid, and leukocyte IFN-alpha by monoclonal antibodies. Viscomi GC; Antonelli G; Bruno C; Scapol L; Malavasi F; Funaro A; Simeoni E; Pestka S; De Pisa F; Dianzani F J Interferon Cytokine Res; 1999 Apr; 19(4):319-26. PubMed ID: 10334382 [TBL] [Abstract][Full Text] [Related]
29. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077 [TBL] [Abstract][Full Text] [Related]
30. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. Antonelli G; Currenti M; Turriziani O; Dianzani F J Infect Dis; 1991 Apr; 163(4):882-5. PubMed ID: 1901335 [TBL] [Abstract][Full Text] [Related]
31. Successful re-treatment of an anti-interferon resistant polycythaemia vera patient with lymphoblastoid interferon-alpha N1 and in vitro studies on the specificity of the antibodies. Brand CM; Leadbeater L; Budiman R; Lechner K; Gisslinger H Br J Haematol; 1994 Jan; 86(1):216-8. PubMed ID: 8011536 [TBL] [Abstract][Full Text] [Related]
32. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group. Prümmer O Cancer; 1993 Mar; 71(5):1828-34. PubMed ID: 8448744 [TBL] [Abstract][Full Text] [Related]
33. Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2. Nolte KU; Günther G; von Wussow P Eur J Immunol; 1996 Sep; 26(9):2155-9. PubMed ID: 8814261 [TBL] [Abstract][Full Text] [Related]
34. Differential in vitro effects of recombinant alpha-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigens. Murray JL; Stuckey SE; Pillow JK; Rosenblum MG; Gutterman JU J Biol Response Mod; 1988 Apr; 7(2):152-61. PubMed ID: 3129542 [TBL] [Abstract][Full Text] [Related]
35. Binding of human recombinant 125I-interferon gamma to receptors on human cells. Littman SJ; Faltynek CR; Baglioni C J Biol Chem; 1985 Jan; 260(2):1191-5. PubMed ID: 3155725 [TBL] [Abstract][Full Text] [Related]
36. Gamma interferon augments Fc gamma receptor-mediated dengue virus infection of human monocytic cells. Kontny U; Kurane I; Ennis FA J Virol; 1988 Nov; 62(11):3928-33. PubMed ID: 2459406 [TBL] [Abstract][Full Text] [Related]
37. Analysis of the role of interferon-gamma, interleukin 2 and a third factor distinct from interferon-gamma and interleukin 2 in human B cell proliferation. Evidence that they act at different times after B cell activation. Romagnani S; Giudizi GM; Almerigogna F; Biagiotti R; Alessi A; Mingari C; Liang CM; Moretta L; Ricci M Eur J Immunol; 1986 Jun; 16(6):623-9. PubMed ID: 3087756 [TBL] [Abstract][Full Text] [Related]
38. Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis. Ikeda Y; Toda G; Hashimoto N; Umeda N; Miyake K; Yamanaka M; Kurokowa K Clin Exp Immunol; 1991 Jul; 85(1):80-4. PubMed ID: 1906385 [TBL] [Abstract][Full Text] [Related]
39. Autoantibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFN-alpha 2b and human IFN-gamma in healthy blood donors. Ross C; Hansen MB; Schyberg T; Berg K Clin Exp Immunol; 1990 Oct; 82(1):57-62. PubMed ID: 2119920 [TBL] [Abstract][Full Text] [Related]
40. Immunochemical characterization of human antibodies to lymphoblastoid interferon. Thurmond LM; Reese MJ Clin Exp Immunol; 1991 Dec; 86(3):514-9. PubMed ID: 1747959 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]